Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Basic) (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of EPS (Basic) data on record, last reported at -$0.34 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 24.17% year-over-year to -$0.34; the TTM value through Sep 2025 reached -$0.34, up 24.17%, while the annual FY2023 figure was $3.14, 410.41% up from the prior year.
  • EPS (Basic) reached -$0.34 in Q3 2025 per CYCN's latest filing, up from -$0.59 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $11.29 in Q3 2022 and bottomed at -$11.84 in Q2 2022.
  • Average EPS (Basic) over 5 years is -$0.2, with a median of -$0.32 recorded in 2022.
  • The widest YoY moves for EPS (Basic): up 5008.7% in 2022, down 2473.91% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at -$0.24 in 2021, then skyrocketed by 33.33% to -$0.16 in 2022, then surged by 3763.28% to $5.86 in 2023, then plummeted by 96.6% to $0.2 in 2024, then plummeted by 269.84% to -$0.34 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.34 in Q3 2025, -$0.59 in Q2 2025, and -$0.57 in Q1 2025.